Intellia Therapeutics
Stock Forecast, Prediction & Price Target
Intellia Therapeutics Financial Estimates
Intellia Therapeutics Revenue Estimates
Intellia Therapeutics EBITDA Estimates
Intellia Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $33.05M N/A | $52.12M 57.68% | $36.27M -30.40% | Avg: $67.89M Low: $67.89M High: $67.89M avg. 87.17% | Avg: $97.52M Low: $97.52M High: $97.52M avg. 43.63% | Avg: $644.14M Low: $644.14M High: $644.14M avg. 560.51% | Avg: $1.90B Low: $1.90B High: $1.90B avg. 195.99% |
Net Income
% change YoY
| $-259.71M N/A | $-490.20M -88.74% | $-481.19M 1.83% | Avg: $-478.30M Low: $-478.30M High: $-478.30M avg. 0.60% | Avg: $-521.54M Low: $-521.54M High: $-521.54M avg. -9.04% | Avg: $-146.66M Low: $-146.66M High: $-146.66M avg. 71.87% | Avg: $478.49M Low: $478.49M High: $478.49M avg. 426.25% |
EBITDA
% change YoY
| $-267.85M N/A | $-444.67M -66.01% | $-506.31M -13.86% | Avg: $-67.89M Low: $-67.89M High: $-67.89M avg. 86.58% | Avg: $-97.52M Low: $-97.52M High: $-97.52M avg. -43.63% | Avg: $-644.14M Low: $-644.14M High: $-644.14M avg. -560.51% | Avg: $-1.90B Low: $-1.90B High: $-1.90B avg. -195.99% |
EPS
% change YoY
| -$3.66 N/A | -$6.37 -74.04% | -$5.42 14.91% | Avg: -$5.39 Low: -$5.39 High: -$5.39 avg. 0.58% | Avg: -$5.88 Low: -$5.88 High: -$5.88 avg. -9.04% | Avg: -$1.65 Low: -$1.65 High: -$1.65 avg. 71.87% | Avg: $5.39 Low: $5.39 High: $5.39 avg. 426.25% |
Operating Expenses
% change YoY
| $300.90M N/A | $510.28M 69.58% | $551.56M 8.08% | Avg: $119.62M Low: $119.62M High: $119.62M avg. -78.31% | Avg: $171.81M Low: $171.81M High: $171.81M avg. 43.63% | Avg: $1.13B Low: $1.13B High: $1.13B avg. 560.51% | Avg: $3.35B Low: $3.35B High: $3.35B avg. 195.99% |
FAQ
What is Intellia Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 122.42% in 2025-2028.
We have gathered data from N/A analysts. Their low estimate is -478.30M, average is -478.30M and high is -478.30M.
What is Intellia Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 221.82% in 2025-2028.
We have gathered data from N/A analysts. Their low revenue estimate is $67.89M, average is $67.89M and high is $67.89M.
What is Intellia Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 122.42% in 2025-2028.
We have gathered data from N/A analysts. Their low earnings per share estimate is -$5.39, average is -$5.39 and high is $-5.38.